Evaxion Biotech A/S
EVAXEvaxion Biotech A/S reported revenue of $7.5 million for FY 2025, up 125% from $3.3 million in FY 2024, driven by a $7.5 million upfront payment from MSD upon exercising its option to license EVX-B3 vaccine candidate, plus minor Gates Foundation grants.
NASDAQ
Healthcare
Biotechnology
$3.74
-0.20(-5.08%)
52W $1.31 – $11.01
AI-generated
Evaxion Biotech A/S reported revenue of $7.5 million for FY 2025, up 125% from $3.3 million in FY 2024, driven by a $7.5 million upfront payment from MSD upon exercising its option to license EVX-B3 vaccine candidate, plus minor Gates Foundation grants.
$24MMkt Cap
$7MRev TTM
-$8MNI TTM
-3.2xP/E TTM
Latest Earnings
20-F
FY FY2025Mar 4, 2026Evaxion Biotech A/S reported revenue of $7.5 million for FY 2025, up 125% from $3.3 million in FY 2024, driven by a $7.5 million upfront payment from MSD upon exercising its option to license EVX-B3 vaccine candidate, plus minor Gates Foundation grants. Net loss narrowed to $7.7 million from $10.6 million, reflecting revenue growth and stable operating expenses at $16.8...
Fundamentals
How The Business Makes Money
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Industry Biotechnology
Company Profile
CIK0001828253
ISINUS29970R3030
CUSIP29970R303
Phone45 53 53 18 50
AddressDr. Neergaards Vej, Horsholm, 2970, DK
SEC EDGAR